News

Our New Technology Got U.S. Invention Patent License

2015-11-06

On March 1st, 2016, the patent “antimicrobial peptide and methods of preparation and use” which was independently developed by Jiangsu ProteLight got the authorization of the U.S. invention patent license officially (patent license NO.US9, 273, 095B2 ).

Previous article

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

Next article

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China